Personalis Stock News

Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Personalis, Inc. (NASDAQ:PSNL) by 0.2% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 1,085,026 shares of the companys stock after purchasing an additional 2,111 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 2.44% of Personalis []

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 4,184 shares of the businesss stock in a transaction that occurred on Thursday, December 2nd. The stock was sold at an average price of $12.92, for a total transaction of $54,057.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through []

Related Stocks: PSNL ,

Credit Suisse AG grew its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 6.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,734 shares of the companys stock after acquiring an additional 1,086 shares during the period. Credit Suisse AGs holdings in Personalis were []

Metropolitan Life Insurance Co NY lifted its holdings in Personalis, Inc. (NASDAQ:PSNL) by 146,300.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,248 shares of the companys stock after purchasing an additional 10,241 shares during the period. Metropolitan Life Insurance []

Personalis (NASDAQ:PSNL) updated its fourth quarter 2021 earnings guidance on Thursday. The company provided EPS guidance of $-0.510-$-0.490 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.490. The company issued revenue guidance of $20.20 million-$20.40 million, compared to the consensus revenue estimate of $20.39 million.Personalis also updated its FY 2021 guidance […]

Shares of Personalis, Inc. (NASDAQ:PSNL) have earned a consensus rating of Hold from the twelve research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 []

UBS Asset Management Americas Inc. lifted its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 34.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,951 shares of the companys stock after purchasing an additional 10,251 shares during the period. UBS Asset Management Americas Inc. owned []

Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West sold 2,348 shares of Personalis stock in a transaction that occurred on Wednesday, November 17th. The shares were sold at an average price of $17.04, for a total transaction of $40,009.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC []

Viridian Therapeutics (NASDAQ:VRDN) and Personalis (NASDAQ:PSNL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Viridian Therapeutics and []

Personalis' (PSNL) CEO John West on Q3 2021 Results - Earnings Call Transcript

MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Expands Leadership Team with Appointment of Robert Bruce, Vice President of Reimbursement

The stock price of Personalis Inc (NASDAQ: PSNL) increased by over 3.4% today. This is why it happened.